BRISTOL-MYERS SQUIBB COMPANY Derivative Liability
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Derivative Liability of $50.00 million as of 2010-09-30, per its 10-Q filed 2010-10-26.
Discontinued › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2010-10-26
- 2010-09-30: Derivative Liability $50.00M.
- 2009-12-31: Derivative Liability $37.00M.
| Period end | Derivative Liability |
|---|---|
| 2010-09-30 | $50.00M 10-Q · filed 2010-10-26 |
| 2009-12-31 | $37.00M 10-Q · filed 2010-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |